SYRE Stock Overview
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Spyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.20 |
| 52 Week High | US$47.97 |
| 52 Week Low | US$2.66 |
| Beta | 2.93 |
| 1 Month Change | -18.01% |
| 3 Month Change | 70.64% |
| 1 Year Change | 866.23% |
| 3 Year Change | -80.00% |
| 5 Year Change | -79.64% |
| Change since IPO | -87.59% |
Recent News & Updates
Recent updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Feb 10
Aeglea Biotherapeutics CFO Charles York to step down
Feb 03Shareholder Returns
| SYRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -3.9% | -3.1% |
| 1Y | 866.2% | -1.8% | 20.9% |
Return vs Industry: SYRE exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: SYRE exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| SYRE volatility | |
|---|---|
| SYRE Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SYRE's share price has been volatile over the past 3 months.
Volatility Over Time: SYRE's weekly volatility has decreased from 48% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 30 | Cameron Turtle | www.spyre.com |
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
Spyre Therapeutics, Inc. Fundamentals Summary
| SYRE fundamental statistics | |
|---|---|
| Market cap | US$1.37b |
| Earnings (TTM) | -US$338.79m |
| Revenue (TTM) | US$886.00k |
1,537x
P/S Ratio-4.0x
P/E RatioIs SYRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYRE income statement (TTM) | |
|---|---|
| Revenue | US$886.00k |
| Cost of Revenue | US$84.05m |
| Gross Profit | -US$83.16m |
| Other Expenses | US$255.63m |
| Earnings | -US$338.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.26 |
| Gross Margin | -9,385.89% |
| Net Profit Margin | -38,238.15% |
| Debt/Equity Ratio | 0% |
How did SYRE perform over the long term?
See historical performance and comparison